Bipartisan Health Insurance Affordability Act
HB6501, titled the Bipartisan Health Insurance Affordability Act, would extend and modify the enhanced premium tax credit for coverage purchased through Affordable Care Act exchanges. For tax years beginning after December 31, 2025, it would continue the expanded subsidy structure through 2027, including reduced premium contributions for households up to 150% of the poverty line, a sliding scale for households between 150% and 200% of poverty, and eligibility for credits for households above 400% of the poverty line up to 700% of poverty. The bill also requires exchanges to notify eligible individuals of the amount of their premium tax credit before enrollment, extends the 2026 open enrollment period, and creates new options for some enrollees to prepay premiums and direct part of the premium tax credit into a health savings account.
The bill also adds a set of exchange integrity and consumer-protection provisions. It directs the Secretary of Health and Human Services to establish verification and audit processes for agent- and broker-assisted enrollments, imposes civil and criminal penalties for fraudulent conduct by agents and brokers, requires disclosure and oversight of field marketing and third-party marketing organizations, and mandates quarterly checks of the Death Master File to remove deceased individuals from exchange plans. In addition, it would require exchanges to prioritize continuity of coverage and prohibit disenrollment without the individual’s consent in the verification process.
A major second component of the bill addresses pharmacy benefit managers in Medicare Part D and Medicare Advantage prescription drug plans. Beginning in 2029, PBMs would face new written-agreement, transparency, audit, disgorgement, and reporting requirements, including rules aimed at ensuring full pass-through of rebates and other remuneration to plan sponsors, clearer disclosure of pricing and compensation structures, and limits on price-based compensation arrangements. The bill also directs GAO and MedPAC to study and report on PBM compensation and drug pricing practices, and appropriates funding to CMS, HHS OIG, and MedPAC to implement and analyze these changes. It further amends ERISA to require full rebate pass-through in group health plan PBM arrangements, while creating an exception for certain fiduciaries that act in good faith and promptly seek correction when a service provider fails to remit amounts.
The overall sentiment reflected in the bill’s title and structure is bipartisan and reform-oriented, with the measure framed as improving affordability, consumer protections, and transparency rather than expanding or contracting coverage broadly. Because there are no committee transcripts or recorded votes in the provided context, there is no documented debate history here; however, the bill’s design suggests an attempt to balance subsidy extension with anti-fraud safeguards and PBM accountability. The most likely areas of contention are the cost and duration of the enhanced premium tax credits, the scope of federal oversight over brokers and marketing organizations, and the extent to which the PBM provisions would alter existing commercial and Medicare drug-pricing arrangements.
HB6501 would amend the Internal Revenue Code, the Affordable Care Act, the Social Security Act, and ERISA. It would extend ACA premium tax credit enhancements beyond 2025, change exchange enrollment rules, add consumer-notification and anti-fraud requirements, and impose new federal standards on PBMs in Part D, MA-PD, and employer-sponsored health plans. The bill would also create new reporting, audit, and enforcement duties for HHS, Treasury, GAO, MedPAC, and the HHS Inspector General, while affecting exchanges, insurers, brokers, marketing organizations, PBMs, plan sponsors, fiduciaries, and enrollees.
The bill is presented as bipartisan and broadly pro-consumer, with its core goals being affordability, continuity of coverage, and transparency in health insurance and prescription drug pricing. The text suggests support for extending premium assistance and tightening oversight of enrollment and drug-benefit intermediaries. No votes or hearing transcripts were provided, so there is no recorded committee sentiment to summarize beyond the bill’s bipartisan framing and policy direction.
Likely points of contention include whether extending enhanced premium tax credits through 2027 and expanding eligibility up to 700% of poverty is fiscally sustainable, and whether the new exchange verification and broker-penalty regime is too aggressive or burdensome. The PBM title is also likely to draw debate because it imposes extensive disclosure, audit, and rebate pass-through requirements that could affect existing contracting and compensation practices. Additional friction may arise over federal preemption concerns, the treatment of marketing organizations, and the practical implementation of HSA-related premium credit elections and exchange enrollment changes.